Intellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low – Time to Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $11.34 and last traded at $11.66, with a volume of 3223027 shares. The stock had previously closed at $11.41.

Analyst Ratings Changes

A number of brokerages have recently commented on NTLA. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. William Blair restated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Wedbush reaffirmed a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. Chardan Capital boosted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Finally, Oppenheimer reduced their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Trading Up 4.8 %

The company’s 50 day simple moving average is $14.15 and its 200-day simple moving average is $19.53. The firm has a market cap of $1.24 billion, a P/E ratio of -2.25 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter last year, the company earned ($1.38) EPS. The firm’s revenue for the quarter was down 24.1% on a year-over-year basis. On average, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Intellia Therapeutics by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 364,306 shares of the company’s stock valued at $8,153,000 after purchasing an additional 2,301 shares during the period. Allspring Global Investments Holdings LLC grew its position in Intellia Therapeutics by 22.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 10,887 shares of the company’s stock valued at $244,000 after buying an additional 1,993 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Intellia Therapeutics by 21.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,587 shares of the company’s stock valued at $617,000 after buying an additional 4,824 shares during the last quarter. Rhumbline Advisers raised its position in Intellia Therapeutics by 5.3% in the second quarter. Rhumbline Advisers now owns 175,335 shares of the company’s stock worth $3,924,000 after acquiring an additional 8,797 shares during the period. Finally, Arizona State Retirement System boosted its stake in shares of Intellia Therapeutics by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 25,648 shares of the company’s stock worth $574,000 after acquiring an additional 2,267 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.